RR: 4.85 Target: 33.5%, 21d Price has been downward since the share offering announcement. Run up to ER is possible.
Ichimoku cross, positive trend possible 2021 could bring a CBD product if the FDA relaxes restrictions.
RR: 2.45 Target: 23%, 46d Looks like the downward trend will continue. Re-evaluate in 20 days. The run up to earnings should be nice.
Possible breakout after consolidation
Looking to add around $14. Breakout (up or down) will happen soon regardless of merger news.
RR: 3.9 Target: 16%, 11d
